Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers.
- 1 March 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 79 (3), 666-673
- https://doi.org/10.1161/01.cir.79.3.666
Abstract
After addition of a low concentration of thrombin to normal plasma, a progressive and significant increase in crosslinked fibrin polymers was found by sodium dodecyl sulfate agarose gel electrophoresis, reaching 27% of total fibrinogen and fibrin before gel formation. As measured by enzyme-linked immunosorbent assay with a monoclonal antibody specific for an epitope near the gamma gamma crosslink site, increased immunoreactivity of plasma did not occur after adding thrombin despite formation of crosslinked fibrin polymers, which indicates that the antibody does not recognize the epitope in the polymers. Addition of tissue-type plasminogen activator (t-PA) to plasma resulted in a more rapid degradation of fibrin polymers than of fibrinogen, indicating that the fibrin specificity of t-PA is retained with soluble fibrin. Coincident with degradation of plasma crosslinked fibrin polymers, plasma DD immunoreactivity increased 70-fold from 50.3 +/- 4.5 (mean +/- SD) to 3,560 +/- 1,235 ng/ml. The presence of increased crosslinked fibrin polymers produced by adding thrombin to plasma significantly increased maximum immunoreactivity after t-PA-induced degradation to 18,500 +/- 11,780 ng/ml. The increase in DD immunoreactivity was dependent on t-PA concentration; no elevation occurred below 0.01 micrograms/ml, and maximal increases occurred above 100 micrograms/ml. Analysis of gel electrophoretic patterns of thrombin and t-PA-treated plasma samples suggests that the DD reactivity of t-PA-treated plasma is mainly due to degradation of soluble crosslinked fibrin polymers. Our findings indicate that plasmic degradation of soluble fibrin polymers in plasma may be an important source of fragment DD during thrombolytic therapy.This publication has 39 references indexed in Scilit:
- Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.Journal of Clinical Investigation, 1987
- Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systemsBritish Journal of Haematology, 1985
- Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.Journal of Clinical Investigation, 1985
- Measurement of desarginine fibrinopeptide B in human blood.Journal of Clinical Investigation, 1981
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- Characterization of Serum Fibrinogen and Fibrin Fragments Produced during Disseminated Intravascular CoagulationBritish Journal of Haematology, 1978
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978
- Measurement of Fibrinopeptide A in Human BloodJournal of Clinical Investigation, 1974
- γ-γ Cross-linking sites in human and bovine fibrinBiochemistry, 1971
- Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporationJournal of Clinical Investigation, 1969